[go: up one dir, main page]

DK0576643T3 - Oxycodonpræparater med styret frigivelse - Google Patents

Oxycodonpræparater med styret frigivelse

Info

Publication number
DK0576643T3
DK0576643T3 DK92925406.8T DK92925406T DK0576643T3 DK 0576643 T3 DK0576643 T3 DK 0576643T3 DK 92925406 T DK92925406 T DK 92925406T DK 0576643 T3 DK0576643 T3 DK 0576643T3
Authority
DK
Denmark
Prior art keywords
mean
oxycodone
hrs
admin
salt
Prior art date
Application number
DK92925406.8T
Other languages
English (en)
Other versions
DK0576643T5 (da
Inventor
Benjamin Oshlack
Mark Chasin
John Joseph Minogue
Robert Francis Kaiko
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25178688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0576643(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of DK0576643T3 publication Critical patent/DK0576643T3/da
Application granted granted Critical
Publication of DK0576643T5 publication Critical patent/DK0576643T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Fluid Pressure (AREA)
  • Polyethers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK92925406T 1991-11-27 1992-11-25 Oxycodonpræparater med styret frigivelse DK0576643T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/800,549 US5266331A (en) 1991-11-27 1991-11-27 Controlled release oxycodone compositions
PCT/US1992/010146 WO1993010765A1 (en) 1991-11-27 1992-11-25 Controlled release oxycodone compositions

Publications (2)

Publication Number Publication Date
DK0576643T3 true DK0576643T3 (da) 1997-04-21
DK0576643T5 DK0576643T5 (da) 2004-11-22

Family

ID=25178688

Family Applications (10)

Application Number Title Priority Date Filing Date
DK03006021T DK1327445T3 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med kontrolleret afgivelse
DK04005576T DK1438959T3 (da) 1991-11-27 1992-11-25 Oxycodonsammensætninger med kontrolleret frigivelse
DK92925406T DK0576643T5 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med styret frigivelse
DK04026291T DK1502592T3 (da) 1991-11-27 1992-11-25 Oxycodonsammensætninger med kontrolleret frigivelse
DK07100188.7T DK1810679T3 (da) 1991-11-27 1992-11-25 Oxycodonsammensætninger med kontrolleret frigivelse
DK02008249T DK1258246T3 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med kontrolleret afgivelse
DK96102992.3T DK0722730T4 (da) 1991-11-27 1992-11-25 Sammensætninger af oxycodon med styret frigivelse
DK03006020T DK1325746T3 (da) 1991-11-27 1992-11-25 Oxycodonsaltpræparater med kontrolleret afgivelse
DK03006022T DK1327446T4 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med kontrolleret afgivelse
DK200000364U DK200000364U3 (da) 1991-11-27 2000-12-08 Oxycodenpræparater med kontrolleret afgivelse

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK03006021T DK1327445T3 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med kontrolleret afgivelse
DK04005576T DK1438959T3 (da) 1991-11-27 1992-11-25 Oxycodonsammensætninger med kontrolleret frigivelse

Family Applications After (7)

Application Number Title Priority Date Filing Date
DK04026291T DK1502592T3 (da) 1991-11-27 1992-11-25 Oxycodonsammensætninger med kontrolleret frigivelse
DK07100188.7T DK1810679T3 (da) 1991-11-27 1992-11-25 Oxycodonsammensætninger med kontrolleret frigivelse
DK02008249T DK1258246T3 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med kontrolleret afgivelse
DK96102992.3T DK0722730T4 (da) 1991-11-27 1992-11-25 Sammensætninger af oxycodon med styret frigivelse
DK03006020T DK1325746T3 (da) 1991-11-27 1992-11-25 Oxycodonsaltpræparater med kontrolleret afgivelse
DK03006022T DK1327446T4 (da) 1991-11-27 1992-11-25 Oxycodonpræparater med kontrolleret afgivelse
DK200000364U DK200000364U3 (da) 1991-11-27 2000-12-08 Oxycodenpræparater med kontrolleret afgivelse

Country Status (30)

Country Link
US (13) US5266331A (da)
EP (15) EP2340833A3 (da)
JP (2) JP3375960B2 (da)
KR (1) KR100280973B1 (da)
CN (2) CN1165307C (da)
AT (9) ATE226822T1 (da)
AU (1) AU657027B2 (da)
BG (1) BG61753B1 (da)
BR (1) BR9205498A (da)
CA (1) CA2098738C (da)
CZ (4) CZ298499B6 (da)
DE (10) DE69232837T3 (da)
DK (10) DK1327445T3 (da)
ES (9) ES2096781T3 (da)
FI (7) FI113152B (da)
GR (1) GR3022273T3 (da)
HU (10) HU224075B1 (da)
IL (1) IL103909A (da)
MX (1) MX9302968A (da)
NO (6) NO307028B3 (da)
PH (1) PH31679A (da)
PL (2) PL172236B1 (da)
PT (8) PT1327445E (da)
RO (1) RO115112B1 (da)
RS (3) RS50056B (da)
RU (1) RU2122411C1 (da)
SK (1) SK280295B6 (da)
WO (1) WO1993010765A1 (da)
YU (1) YU49495B (da)
ZA (1) ZA929227B (da)

Families Citing this family (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
HU218673B (hu) * 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
EP0888111B1 (en) * 1996-03-08 2003-05-21 Nycomed Danmark A/S Modified release multiple-units dosage composition
WO1997045091A2 (en) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
SI1041987T1 (sl) 1997-12-22 2006-10-31 Euro Celtique Sa Farmacevtska oralna dozirna oblika, ki obsega kombinacijo opioidnega agonista in naltreksona
AU755790B2 (en) * 1997-12-22 2002-12-19 Euro-Celtique S.A. A method of preventing abuse of opioid dosage forms
EP0955048A1 (en) * 1998-03-12 1999-11-10 Akzo Nobel N.V. Making dosage units using low shear granulation
IL128818A0 (en) * 1998-03-12 2000-01-31 Akzo Nobel Nv Making dosage units using low shear granulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ES2374717T3 (es) * 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
ATE431145T1 (de) 2000-02-08 2009-05-15 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
CN100356907C (zh) * 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
US7276250B2 (en) * 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004032A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003015531A2 (en) * 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP1484056B1 (en) * 2002-02-21 2013-08-14 Otsuka Pharmaceutical Co., Ltd. Sustained release preparations and process for producing the same
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CN1646102B (zh) 2002-04-05 2012-08-15 欧洲凯尔蒂克公司 含有羟氢可待酮和烯丙羟吗啡酮的药物制剂
CN1665482A (zh) * 2002-04-29 2005-09-07 阿尔扎公司 羟可待酮控制输送给药的方法和剂型
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
JP2005528423A (ja) * 2002-05-31 2005-09-22 アルザ・コーポレーシヨン オキシコドンの変動性投薬用量の浸透圧的送達のための剤形および組成物
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2003247876B2 (en) 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US7168140B2 (en) * 2002-08-08 2007-01-30 Milliken & Company Flame resistant fabrics with improved aesthetics and comfort, and method of making same
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
DK1551372T3 (da) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sekvestreringsunderenhed og relaterede sammensætninger og fremgangsmåder
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
AU2003299659A1 (en) * 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
MXPA05009757A (es) * 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004232370B2 (en) 2003-04-21 2009-12-10 Euro-Celtique S.A. Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
AU2004258894B2 (en) * 2003-07-17 2010-06-03 Patheon Softgels Inc. Controlled release preparations
WO2005016313A1 (de) * 2003-08-06 2005-02-24 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20050053659A1 (en) 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
EP1677768A4 (en) * 2003-10-03 2011-06-29 Elite Lab Inc PROLONGED RELEASE OPIOID FORMULATIONS AND METHOD OF USING THE FORMULATIONS
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
SI1691892T1 (sl) * 2003-12-09 2007-08-31 Euro Celtique Sa Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1729730B1 (en) * 2004-03-30 2009-01-07 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
EP1765292B1 (en) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EA010627B1 (ru) * 2004-09-01 2008-10-30 Еуро-Селтик С.А. Совокупность дозированных лекарственных форм, содержащих опиоид
DK2767292T3 (da) 2004-09-17 2016-12-19 Durect Corp Vedvarende lokalbedøvelsessammensætning indeholdende saib
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
RU2401125C2 (ru) 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EA015615B1 (ru) 2005-01-28 2011-10-31 Еуро-Селтик С.А. Устойчивые к спиртам лекарственные формы
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CN1957909B (zh) * 2005-10-31 2013-09-11 阿尔扎公司 降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法
EP1849460A3 (en) * 2005-10-31 2007-11-14 ALZA Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
DK1993559T3 (da) 2006-02-03 2016-10-03 Opko Renal Llc Behandling af vitamin D-mangel og -defekt med 25-hydroxyvitamin D2 og 25-hydroxyvitamin D3
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
EP1995276A4 (en) * 2006-03-15 2009-09-09 Johoku Chemical Co Ltd STABILIZED POLYOLEFIN RESIN AND METHOD FOR STABILIZING POLYOLEFIN RESIN
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SI2526932T1 (sl) 2006-06-19 2017-07-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavek
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
CA2659122C (en) * 2006-08-04 2016-08-23 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
US7872013B2 (en) * 2006-08-16 2011-01-18 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
FI3225243T3 (fi) 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
DK2481400T3 (da) 2007-04-25 2014-09-29 Opko Ip Holdings Ii Inc Orale præparater med kontrolleret frigivelse omfattende en vitamin D-forbindelse og en voksagtig bærer
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
MX336861B (es) * 2007-09-13 2016-02-04 Cima Labs Inc Formulacion de farmaco resistente al abuso.
DE502007002695D1 (de) 2007-11-09 2010-03-11 Acino Pharma Ag Retardtabletten mit Hydromorphon
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
EP2249811A1 (en) * 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
KR101094231B1 (ko) 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US20100063368A1 (en) * 2008-04-24 2010-03-11 Searete Llc, A Limited Liability Corporation Computational system and method for memory modification
US20090270694A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20090312668A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100017001A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US9239906B2 (en) * 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20100125561A1 (en) * 2008-04-24 2010-05-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271009A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment modification methods and systems
US20100130811A1 (en) * 2008-04-24 2010-05-27 Searete Llc Computational system and method for memory modification
US20100100036A1 (en) * 2008-04-24 2010-04-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US9282927B2 (en) * 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US8876688B2 (en) * 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100081861A1 (en) * 2008-04-24 2010-04-01 Searete Llc Computational System and Method for Memory Modification
US20090312595A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for memory modification
US9649469B2 (en) * 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US8930208B2 (en) * 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US9026369B2 (en) * 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9064036B2 (en) * 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20090271375A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment selection methods and systems
US20090269329A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination Therapeutic products and systems
US20090271347A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100041958A1 (en) * 2008-04-24 2010-02-18 Searete Llc Computational system and method for memory modification
US9449150B2 (en) * 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20100069724A1 (en) * 2008-04-24 2010-03-18 Searete Llc Computational system and method for memory modification
US20100041964A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100022820A1 (en) * 2008-04-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
NZ588863A (en) 2008-05-09 2012-08-31 Gruenenthal Chemie Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
AU2009203070A1 (en) * 2008-05-20 2009-12-10 Qrxpharma Limited Dual opioid pain therapy
JP5406288B2 (ja) * 2008-07-07 2014-02-05 ユーロ−セルティーク エス．エイ． 尿閉を治療するためのオピオイド拮抗薬の使用
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US8811578B2 (en) * 2009-03-23 2014-08-19 Telemanager Technologies, Inc. System and method for providing local interactive voice response services
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
CN102573806B (zh) 2009-07-22 2015-02-25 格吕伦塔尔有限公司 用于对氧化敏感的阿片类物质的抗破坏剂型
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
US20110046173A1 (en) * 2009-08-24 2011-02-24 Warren Charles Stern Combination analgesic opioid pain therapy
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
JP5819329B2 (ja) * 2010-03-09 2015-11-24 アルカーメス ファーマ アイルランド リミテッド アルコール耐性腸溶性医薬組成物
EP3636280B1 (en) 2010-03-29 2025-05-14 EirGen Pharma Ltd. Methods and compositions for reducing parathyroid levels
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
WO2012003968A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
ES2444591T3 (es) 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
RS56344B1 (sr) 2010-12-22 2017-12-29 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
SG191872A1 (en) 2011-02-02 2013-08-30 Alpharma Pharmaceuticals Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
KR20160135373A (ko) 2011-03-23 2016-11-25 아이언쇼어 파마슈티컬즈 앤드 디벨롭먼트, 인크. 주의력 결핍 장애의 치료를 위한 방법 및 조성물
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
PT2726064T (pt) * 2011-06-30 2016-12-28 Develco Pharma Schweiz Ag Forma de dosagem oral de libertação controlada compreendendo oxicodona
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
ES2655900T3 (es) 2011-07-29 2018-02-22 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
EP2819656A1 (en) * 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013204592A1 (en) * 2012-04-09 2013-10-24 QRxPharma Ltd. Controlled release formulations of opioids
SG11201406025UA (en) 2012-04-17 2014-11-27 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3122336A4 (en) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
MX395229B (es) 2016-03-28 2025-03-21 Opko Ireland Global Holdings Ltd Métodos de tratamiento con vitamina d.
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US12201629B2 (en) 2017-06-30 2025-01-21 Purdue Pharma L.P. Method of treatment and dosage forms thereof
EP3703724A1 (en) 2017-11-02 2020-09-09 NatureCeuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법
CN115702888B (zh) * 2021-08-13 2024-05-28 合肥立方制药股份有限公司 一种盐酸羟考酮渗透泵缓释片及其制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US291883A (en) * 1884-01-15 Faucet
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
NL263733A (da) * 1960-04-19 1900-01-01
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) † 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3922339A (en) * 1974-06-20 1975-11-25 Kv Pharm Co Sustained release medicant
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3946899A (en) * 1975-02-07 1976-03-30 Allain Charles V Sugar cane planter
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
DE2966893D1 (en) * 1978-10-02 1984-05-17 Purdue Research Foundation Foods and pharmaceutical coating composition, method of preparation and products so coated
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
ATE84713T1 (de) * 1985-05-13 1993-02-15 Miles Inc Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3750145T2 (de) † 1986-06-10 1994-11-03 Euro Celtique Sa Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) † 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) † 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US4862598A (en) * 1987-10-01 1989-09-05 Perceptron, Inc. Quick connect/disconnect repeatable sensor mounting apparatus
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JPH01287019A (ja) * 1988-05-12 1989-11-17 Tanabe Seiyaku Co Ltd 徐放性製剤
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2648020B1 (fr) * 1989-06-12 1992-03-13 Rhone Poulenc Sante Utilisation de compositions degradables par voie enzymatique pour l'enrobage d'additifs alimentaires destines aux ruminants
DK161743C (da) * 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5248516A (en) * 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5206030A (en) * 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
DE59105613D1 (de) * 1990-08-24 1995-07-06 Spirig Ag Verfahren zur Herstellung von Pellets.
JP2669945B2 (ja) * 1991-02-05 1997-10-29 ファナック株式会社 ならい制御装置
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
DE69222847T3 (de) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) † 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) † 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5286493A (en) † 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations

Also Published As

Publication number Publication date
EP2340833A3 (en) 2012-09-12
ATE261727T1 (de) 2004-04-15
FI118250B (fi) 2007-09-14
BR9205498A (pt) 1994-06-07
DE69214802T2 (de) 1997-05-07
CZ176493A3 (en) 1994-04-13
HU228058B1 (en) 2012-09-28
SK92293A3 (en) 1994-04-06
US20030099704A1 (en) 2003-05-29
DK0722730T3 (da) 2002-11-25
EP1325746A1 (en) 2003-07-09
KR100280973B1 (ko) 2001-02-01
PT1810679E (pt) 2010-02-18
ES2268189T3 (es) 2007-03-16
DK1438959T3 (da) 2007-09-17
DE69233640D1 (de) 2006-08-24
HK1051803A1 (en) 2003-08-22
DK1327446T4 (da) 2007-12-17
EP1774969A3 (en) 2007-10-03
DK0722730T5 (da) 2003-03-31
MX9302968A (es) 1994-05-31
HU227514B1 (en) 2011-07-28
ATE261725T1 (de) 2004-04-15
ES2215984T5 (es) 2008-03-16
HU0400226D0 (en) 2004-04-28
DK1502592T3 (da) 2007-10-22
HK1073255A1 (en) 2005-09-30
RS50054B (sr) 2008-11-28
PT1258246E (pt) 2004-06-30
RS50056B (sr) 2008-11-28
DE9219234U1 (de) 2001-03-29
NO932661L (no) 1993-09-24
EP1810679B1 (en) 2010-01-06
CN1245958C (zh) 2006-03-22
EP1327446B2 (en) 2007-08-22
ATE360421T1 (de) 2007-05-15
AU657027B2 (en) 1995-02-23
FI20080512A7 (fi) 2008-09-11
EP2243484A2 (en) 2010-10-27
CZ292849B6 (cs) 2003-12-17
HU0400357D0 (en) 2004-04-28
HK1068004A1 (en) 2005-04-22
HK1059210A1 (en) 2004-06-25
JPH06507645A (ja) 1994-09-01
CN1364458A (zh) 2002-08-21
WO1993010765A1 (en) 1993-06-10
FI20070282A7 (fi) 2007-04-12
FI20031890L (fi) 2003-12-22
IL103909A0 (en) 1993-04-04
EP0576643A4 (en) 1994-03-18
EP2106797A3 (en) 2009-11-04
US20040185098A1 (en) 2004-09-23
JP2002370983A (ja) 2002-12-24
DK1258246T3 (da) 2004-07-05
PT1325746E (pt) 2006-11-30
US20060057210A1 (en) 2006-03-16
ATE261726T1 (de) 2004-04-15
DE69233327D1 (de) 2004-04-22
HU227515B1 (en) 2011-07-28
FI118251B (fi) 2007-09-14
US20060165792A1 (en) 2006-07-27
DE69232837T2 (de) 2003-06-18
NO20041939L (no) 1993-05-27
EP0722730B2 (en) 2013-08-07
DE69233326D1 (de) 2004-04-22
PT1502592E (pt) 2007-09-17
HU0401532D0 (en) 2004-09-28
EP1774969A2 (en) 2007-04-18
EP2289517A2 (en) 2011-03-02
FI20031889L (fi) 2003-12-22
FI20070282L (fi) 2007-04-12
US20060165791A1 (en) 2006-07-27
US20040105887A1 (en) 2004-06-03
NO932661D0 (no) 1993-07-23
ATE226822T1 (de) 2002-11-15
CN1087262A (zh) 1994-06-01
HK1059209A1 (en) 2004-06-25
PT1438959E (pt) 2007-07-19
HK1058474A1 (en) 2004-05-21
DE69233691T2 (de) 2008-01-24
HU224075B1 (hu) 2005-05-30
DE69233328D1 (de) 2004-04-22
HU0400227D0 (en) 2004-04-28
ES2215983T3 (es) 2004-10-16
DE69233328T3 (de) 2008-02-07
DK200000364U3 (da) 2001-03-23
BG61753B1 (bg) 1998-05-29
US20010008639A1 (en) 2001-07-19
ZA929227B (en) 1993-07-12
CZ300183B6 (cs) 2009-03-11
EP0722730B1 (en) 2002-10-30
ATE332691T1 (de) 2006-08-15
EP2340833A2 (en) 2011-07-06
CN1165307C (zh) 2004-09-08
HU227815B1 (en) 2012-03-28
HU0302920D0 (en) 2003-11-28
NO20041662L (no) 1993-09-24
HUT69401A (en) 1995-09-28
HU227518B1 (en) 2011-07-28
ES2286523T3 (es) 2007-12-01
EP1438959B1 (en) 2007-04-25
NO996447L (no) 1993-09-24
US5508042A (en) 1996-04-16
DE69233326T2 (de) 2005-03-10
PT1327445E (pt) 2004-07-30
FI20080512L (fi) 2008-09-11
CA2098738A1 (en) 1993-05-28
BG97973A (bg) 1994-05-27
US20040096500A1 (en) 2004-05-20
PL173574B1 (pl) 1998-03-31
IL103909A (en) 1996-09-12
HU0400225D0 (en) 2004-04-28
NO307028B3 (no) 2009-05-25
EP1258246A2 (en) 2002-11-20
DE69232837D1 (de) 2002-12-05
US5549912A (en) 1996-08-27
US20020018810A1 (en) 2002-02-14
CZ298499B6 (cs) 2007-10-17
JP4016074B2 (ja) 2007-12-05
DK1810679T3 (da) 2010-02-08
ATE365041T1 (de) 2007-07-15
EP2243484A3 (en) 2012-01-11
AU3147693A (en) 1993-06-28
DE69233691D1 (de) 2007-06-06
DE69233778D1 (de) 2010-02-25
EP1325746B1 (en) 2006-07-12
HU0400224D0 (en) 2004-04-28
GR3022273T3 (en) 1997-04-30
NO323334B1 (no) 2007-03-26
ES2096781T3 (es) 1997-03-16
FI20031891L (fi) 2003-12-22
DE69233699D1 (de) 2007-08-02
EP1327445B1 (en) 2004-03-17
EP1810679A2 (en) 2007-07-25
EP1810679A3 (en) 2007-10-03
ATE454150T1 (de) 2010-01-15
HU227517B1 (en) 2011-07-28
PH31679A (en) 1999-01-18
FI116658B (fi) 2006-01-31
DK1327445T3 (da) 2004-07-26
NO20041667L (no) 1993-09-24
JP3375960B2 (ja) 2003-02-10
RU2122411C1 (ru) 1998-11-27
NO325483B1 (no) 2008-05-13
CZ286913B6 (cs) 2000-08-16
DE69214802D1 (de) 1996-11-28
EP2106796A2 (en) 2009-10-07
EP1258246B1 (en) 2004-03-17
PL172236B1 (pl) 1997-08-29
EP0576643B1 (en) 1996-10-23
ES2215984T3 (es) 2004-10-16
EP0576643A1 (en) 1994-01-05
EP1258246A3 (en) 2003-01-08
CA2098738C (en) 1999-08-17
EP2106796A3 (en) 2009-11-04
EP2106797A2 (en) 2009-10-07
ATE144418T1 (de) 1996-11-15
DE69232837T3 (de) 2014-01-02
ES2339392T3 (es) 2010-05-19
DK0722730T4 (da) 2013-11-18
EP1438959A1 (en) 2004-07-21
ES2213720T3 (es) 2004-09-01
FI933330A0 (fi) 1993-07-23
ES2186737T5 (es) 2014-01-17
HU9301517D0 (en) 1993-09-28
EP0722730A1 (en) 1996-07-24
RS50055B (sr) 2008-11-28
DK0576643T5 (da) 2004-11-22
NO322378B1 (no) 2006-09-25
FI20031888L (fi) 2003-12-22
EP1327446A1 (en) 2003-07-16
DE69233699T2 (de) 2008-02-28
YU35893A (sh) 1997-03-07
HU226929B1 (en) 2010-03-01
SK280295B6 (sk) 1999-11-08
EP2289517A3 (en) 2012-07-04
DE69233640T2 (de) 2007-06-14
FI118252B (fi) 2007-09-14
FI113152B (fi) 2004-03-15
PT722730E (pt) 2003-03-31
ES2186737T3 (es) 2003-05-16
YU49495B (sh) 2006-08-17
NO318890B1 (no) 2005-05-18
EP1327445A1 (en) 2003-07-16
RO115112B1 (ro) 1999-11-30
FI933330A7 (fi) 1993-07-23
US20060099255A1 (en) 2006-05-11
HU0303097D0 (en) 2003-11-28
DE69233327T2 (de) 2005-03-10
EP1327446B1 (en) 2004-03-17
DK1327446T3 (da) 2004-08-02
EP2289517B1 (en) 2014-05-07
NO996447D0 (no) 1999-12-23
PT1327446E (pt) 2004-06-30
EP1502592A1 (en) 2005-02-02
HU227516B1 (en) 2011-07-28
US5266331A (en) 1993-11-30
EP1502592B1 (en) 2007-06-20
DE69233328T2 (de) 2005-03-10
NO20043264L (no) 1993-09-24
NO307028B1 (no) 2000-01-31
ES2287625T3 (es) 2007-12-16
DK1325746T3 (da) 2006-11-06

Similar Documents

Publication Publication Date Title
DK0576643T3 (da) Oxycodonpræparater med styret frigivelse